Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The combined company will thus produce devices across cardiovascular, diabetes, vision and neuromodulation markets.
Following a 2014 multicentre survey of members aiming to identify any gaps in the status of interventional radiology staffing, the Society of Interventional Radiology (SIR) has published 11 new recommendations to help centres meet the growing demand for services.
BTG has entered into an agreement to acquire Galil Medical, a provider of cryoablation products for the treatment and palliative care of kidney and other cancers.
Since its introduction in the late 80s, endovascular therapy has become increasingly widespread and important. A mini-symposium held at the 2016 Charing Cross Symposium (26–29 April, London, UK), brought to the fore the radiation damage that has occurred to pioneering operators in the field. It also focused on currently available methods to reduce radiation exposure during endovascular procedures.
Oncolytic immunotherapy or virotherapy is not a threat to interventional oncology—on the contrary it is a “huge and urgent” opportunity, said Daniel Sze while delivering the GEST USA Honorary Lecture. He spoke on the topic “Oncolytic virotherapy: A new class of agents to treat cancer.”
The results from a small prospective, randomised single-centre trial, the PREMIERE trial, show that in patients with unresectable hepatocellular carcinoma, there is a significantly longer time to progression with yttrium-90 (Y-90) radioembolization than with conventional transarterial chemoembolization (cTACE).
Researchers said the majority of men with enlarged prostates and lower urinary tract symptoms reported better sleep that resulted in an improved quality of life after they underwent treatment with the procedure.
SurModics has announced enrolment of the first patient in an early feasibility study of its proprietary SurVeil drug-coated balloon (DCB). A press release states that this study is part of the company’s strategy to transform its medical device business from a provider of device coatings, to offering differentiated whole-product solutions to leading medical device customers.
At the 2016 Charing Cross Symposium (26–29 April, London, UK) and the International Vein Congress (28–30 April, Miami, USA) Medtronic unveiled clinical data for the VenaSeal closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease.
In a study comparing multiplanar venography to intravascular ultrasound (IVUS) for diagnosing common or external iliac and common femoral vein stenosis, IVUS imaging was found to change both the treatment plan in 60/100 patients and the number of stents placed in 50/100 patients. Presenter Paul Gagne (Darien, USA) maintained that “without IVUS, iliofemoral vein occlusive disease would have been undertreated in the majority of patients studied”.
SurModics has announced enrolment of the first patient in an early feasibility study of its proprietary SurVeil drug-coated balloon (DCB). A press release states that this study is part of the company’s strategy to transform its medical device business from a provider of device coatings, to offering differentiated whole-product solutions to leading medical device customers.
A study conducted at St Thomas’ Hospital, London, UK, indicates that the VeinCLEAR catheter (RF Medical) produces good results when used in radiofrequency ablation in the treatment of lower extremity superficial venous insufficiency. The study team, led by Adam M Gwozdz, now suggest that “Long-term evaluation of this device is now needed to ensure that these encouraging early results are maintained.”
Endologix has received CE mark for the next-generation Nellix Endovascular Aneurysm Sealing (EVAS) system. The first procedures with the system were performed by associate professor Andrew Holden and Andrew Hill at Auckland City Hospital, Auckland, New Zealand.
Stents, heart valves, ventricular assist devices, and extracorporeal support systems, as well as vascular grafts and access catheters devices, are prone to failure due to the body’s responses at the blood-material interface; clots can form and inflammatory reactions can prevent the device from performing as indicated. Currently, when this occurs, the only solution is to replace the device.
Psoriasis sufferers may face a higher risk of developing abdominal aortic aneurysms, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos